Abstracts Archive - Page 324 of 2425 - ACR Meeting Abstracts

Abstract Number: 1487 • ACR Convergence 2023
Prevalence of Objectively Measured Sleep Disturbance in Systemic Lupus Erythematosus (SLE)
Patti Katz¹, Jinoos Yazdany² and Maria Dall'Era³, ¹University of California San Francisco, San Rafael, CA, ²University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ³University of California San Francisco, San Francisco, CA
Background/Purpose: Self-reported poor sleep is common in SLE, but few studies have objectively measured sleep have been conducted. In general population studies, sleep disorders are…
Abstract Number: 1163 • ACR Convergence 2023
Anti-melanoma Differentiation Associated Gene 5 (Anti-MDA5) Antibody Dermatomyositis: Clinical Features and Outcome in a Racially Diverse Patient Cohort
Sai Koyoda¹, Dawn Wahezi², Xianhong Xie³, Anand Kumthekar⁴, Clement Tagoe³ and Bibi Ayesha⁵, ¹Essen Medical Center, Rahway, NJ, ²Children's Hospital at Montefiore, New Rochelle, NY, ³Albert Einstein College of Medicine, Bronx, NY, ⁴Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ⁵Montefiore Medical Center, Bronx, NY
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody dermatomyositis typically expresses rapidly progressing interstitial lung disease (RP-ILD) and ulcerative skin lesions, with or without muscle involvement.…
Abstract Number: 1284 • ACR Convergence 2023
Baseline Data’s Role in Predicting All-cause Mortality in Chinese Rheumatoid Arthritis Patients: Findings from the China Registry of Rheumatoid Arthritis (CREDIT) Study
Kangping Huang¹, Mucong Li¹, Chen Yu¹, Nan Jiang¹, Jiuliang zhao¹, Qian Wang¹, Peng Yin², Xinping Tian¹, Mengtao Li¹ and Xiaofeng Zeng¹, ¹Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Chinese Center for Disease Control and Prevention, Beijing, China
Background/Purpose: Rheumatoid arthritis (RA) poses significant challenges for patients in China due to prolonged disease duration prior to a definitive diagnosis, resulting in comorbidities and…
Abstract Number: 1427 • ACR Convergence 2023
Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Involvement of Weight-bearing Joint Regions: A Post Hoc Subgroup Analysis of the Phase 3, Randomized, SELECT-PsA 1 and SELECT-PsA 2 Trials
Kristi Mizelle¹, William R Tillett², Mira Ali³, Thomas Iyile³, Tianming Gao³, Arathi Setty³, Jessica A Walsh⁴ and Laura Coates⁵, ¹Tidewater Physicians Multispecialty Group, Newport News, VA, ²Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³AbbVie, Inc., North Chicago, IL, ⁴Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁵University of Oxford, Oxford, United Kingdom
Background/Purpose: Involvement of weight-bearing joints in patients with PsA can be associated with reduced activities of daily living and quality of life. Upadacitinib (UPA) is…
Abstract Number: 1527 • ACR Convergence 2023
Acute Effects of Intravenous Iloprost on Finger Power Doppler Ultrasound in Scleroderma Patients
Sofia Testoni¹, Luca Magnani², Caterina Tomassini³, Alessia Laneri³, Carlo Salvarani⁴ and PIERLUIGI MACCHIONI², ¹Università degli Studi di Modena e Reggio Emilia, San Giovanni in Persiceto, Italy, ²Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, ³Università degli Studi di Modena e Reggio Emilia, Modena, Italy, ⁴Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: So far few studies explored ultrasound (US) as a tool to assess vascular subcutaneous involvement in patients affected by systemic sclerosis (SSc). We aim…
Abstract Number: 1546 • ACR Convergence 2023
Eosinophilic Granulomatosis with Polyangiitis: Clinical Suspicion Red Flags Identification by a Systematic Literature Review and Multidisciplinary Expert Consensus
Ricardo Blanco¹, Iñigo Rúa-Figueroa², Roser Solans³, Maria C Cid⁴, Marina Blanco⁵, Ismael Garcia Moguel⁶, Francisco Perez Grimaldi⁷, Ana Noblejas⁸, Moises Labrador³, Cristian Domingo⁹, Georgina espigol¹⁰, Fernando Sanchez Toril¹¹, Francisco Ortiz-Sanjuán¹², Ebymar Arismendi¹³ and Jose María Alvaro-Gracias¹⁴, ¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ³Internal Medicine Department, H. Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain, ⁴Hospital Clinic Barcelona, Barcelona, Spain, ⁵Pneumology Department, Hospital Universitario de A Coruña, Madrid, Spain, ⁶Allergy Department, Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain, ⁷Pneumology Department, H. University of Jerez, Cádiz, Spain, ⁸Internal Medicine Department, Hospital Universitario La Paz, Madrid, Spain, ⁹Pneumology Department, Corporació Sanitaria Parc Taulí, Universitat Autònoma de Barcelona, Barcelona, Spain, ¹⁰Autoimmune Diseases Department, Hospital Clínic, FCRB-IDIBAPS, Universitat de Barcelona, Barcelona, Spain, ¹¹Pneumology Department, Hospital Arnau Vilanova, Valencia, Spain;, Valencia, Spain, ¹²Hospital Universitario y Politécnico La Fe, Valencia, Spain, ¹³Pneumology Department, Hospital Clínic de Barcelona, Barcelona, Spain, Universitat de Barcelona, Spain and CIBERES, Barcelona, Spain, ¹⁴Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare ANCA-associated vasculitis, characterized histologically by eosinophilic tissue infiltration, necrotizing vasculitis, and eosinophil-rich granulomatous inflammation. The diagnosis…
Abstract Number: 1547 • ACR Convergence 2023
Disease Burden of Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data
Paul Dolin¹, Danuta Kielar¹, Anat Shavit¹, Karina Keogh², Jennifer Rowell¹, Chris Edmonds³, Juliana Meyers⁴, Elizabeth Esterberg⁴, Tram Nham⁴ and Stephanie Chen⁵, ¹AstraZeneca, Cambridge, United Kingdom, ²Mayo Clinic, Rochester, MN, ³AstraZeneca, Gaithersburg, MD, ⁴RTI Health Solutions, Research Triangle Park, NC, ⁵BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare necrotizing small-to-medium vessel vasculitis with a relapsing-remitting course involving prodromal (various allergic reactions), eosinophilic (infiltration into…
Abstract Number: 1463 • ACR Convergence 2023
Predictors of Cognitive Impairment in Individuals with Systemic Lupus Erythematosus
Alexandra Lee¹, Sharon Phillips² and Leslie Crofford³, ¹Meharry Medical College, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University Medical Center, Melbourne, AR
Background/Purpose: The purpose of this study was to investigate factors associated with objective cognitive impairment in patients diagnosed with Systemic Lupus Erythematous (SLE). Subjective complaints…
Abstract Number: 1544 • ACR Convergence 2023
Increased Risk of Severe Infection in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: A Population-based Trend Analysis
Kai Zhao¹, J. Antonio Avina-Zubieta², Hui Xie³, Natasha Dehghan⁴ and John Esdaile², ¹Arthritis Research Canada, Coquitlam, BC, Canada, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Simon Fraser University, Richmond, BC, Canada, ⁴University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a group of multisystem inflammatory diseases. One of the most serious and common side-effects of GC and…
Abstract Number: 1496 • ACR Convergence 2023
Clinical Safety and Efficacy Results from EQUALISE Type B: A Phase 1b Open-label Clinical Study of Itolizumab, a Novel anti-CD6 Therapy, in Subjects with Active Proliferative Lupus Nephritis
Kenneth Kalunian¹, Robert Levin², Sreejith Parameswaran³, nelson kopyt⁴, Stephen Connelly⁵, Eugene Sun⁵, Katie Kim⁵, maple fung⁵ and Manish Rathi⁶, ¹University of California San Diego, La Jolla, CA, ²South Florida University, Tampa, FL, ³JIPMER, New Delhi, India, ⁴LeHigh University, LeHigh, PA, ⁵Equillium, La Jolla, CA, ⁶Postgraduate Institute of Medical education and Research, Chandigarh, India
Background/Purpose: Itolizumab is a first-in-class, non-depleting, monoclonal antibody against the co-stimulatory receptor CD6 that blocks its interaction with ALCAM, to inhibit Teff cell activity and…
Abstract Number: 1426 • ACR Convergence 2023
Distinct Treatment Response Trajectories in Patients with Psoriatic Arthritis Receiving Tofacitinib
Dafna Gladman¹, William R Tillett², David Gruben³, Laura Coates⁴, Stefanie Hahne⁵ and Mikhail Volkov⁶, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Pfizer Inc., Groton, CT, ⁴University of Oxford, Oxford, United Kingdom, ⁵Pfizer Pharma GmbH, Berlin, Germany, ⁶Pfizer BV, Capelle aan den IJssel, Netherlands
Background/Purpose: PsA is a heterogeneous disease, and identifying clinical phenotypes may assist clinical decision making. Patients (pts) treated with advanced therapies demonstrate varying treatment responses.…
Abstract Number: 1312 • ACR Convergence 2023
Uncovering Risk Factors for Adverse Events and Infections in Rheumatoid Arthritis and Rheumatoid Arthritis with Interstitial Lung Disease Under Biologics or Targeted Synthetic DMARDs: Insights from the KOBIO Registry
Ji-Won Kim¹, Ju-Yang Jung¹, Chang-Hee Suh² and Hyoun-Ah Kim¹, ¹Ajou University School of Medicine, Suwon, South Korea, ²Ajou University Hospital, Suwon, South Korea
Background/Purpose: This study aimed to identify risk factors associated with adverse events (AEs) and infections in patients with rheumatoid arthritis (RA) and comorbid interstitial lung…
Abstract Number: 1127 • ACR Convergence 2023
Factors Associated with Vision-Related Quality of Life in Patients with Non-infectious Uveitis: A Longitudinal Analysis
Maria Paula Alvarez Hernandez¹, Inés Pérez Sancristóbal¹, Alfredo Madrid García², Lara Borrego Sanz³, Cristina Hormigos martín¹, Beatriz García Tirado³, Mayte Ariño Gutiérrez³, Cristina lajas Petisco¹, Pedro Arriola Villalobos³, Esperanza Pato Cour³ and Luis Rodríguez Rodríguez¹, ¹Hospital Clinico San Carlos, Madrid, Spain, ²Fundación Investigación Biomédica Hospital Clínico San Carlos, Madrid, Spain, ³Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: Non-infectious uveitis (NIU) are characterized by inflammation of the middle layer of the eye wall and have a significant impact on patients' visual-related quality…
Abstract Number: 1135 • ACR Convergence 2023
The Prescribing Patterns and Role of TNF-α Inhibitors in Treatment of Cardiac Sarcoidosis Patients
Alice Kwon¹, Audrey Liu¹, Sonali Narain², Elena Katzap³ and Galina Marder², ¹Northwell Health, Manhasset, NY, ²Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³Northwell Health, Great NY, NY
Background/Purpose: Cardiac sarcoidosis is one of the most common causes of mortality from sarcoidosis. In this retrospective study, we describe prescribing patterns and compare outcomes between patients treated with conventional immunosuppressive therapies…
Abstract Number: 1615 • ACR Convergence 2023
Therapeutic Hydroxychloroquine Blood Levels Are Cost Effective and May Reduce Health Disparities by Reducing Lupus Hospitalizations
Shivani Garg¹, Giancarlo Valiente², Lexie Kolton³, Callie Saric³, Betty Chewning⁴ and Christie M. Bartels², ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, School of Medicine and Public Health, Madison, WI, ³University of Wisconsin, Madison, WI, ⁴University of Wisconsin, School of Pharmacy, Madison, WI
Background/Purpose: Studies show factors including daily hydroxychloroquine (HCQ) dosing or nonadherence affect blood concentrations risking 6-fold higher lupus (or SLE) flares requiring hospitalization. Given disparities…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].